Poxel (POXEL.PA) Stock Price
Poxel Price
Revenue has compounded at 68.8% per year over the past 9 years to 6.64 M EUR. Poxel's net margin stands at -275.8%, up from -468.1% several years earlier.
Poxel stock price
Poxel business model & stock analysis
Frequently asked questions about Poxel
The business model of Poxel SA revolves around the development and commercialization of innovative drugs to treat metabolic disorders. Poxel SA focuses on the discovery and development of safe and effective therapeutic solutions for diseases such as type 2 diabetes and non-alcoholic steatohepatitis (NASH). By leveraging their expertise in mitochondrial metabolism, the company aims to offer advanced treatment options to patients worldwide. Poxel SA also seeks to collaborate with strategic partners and leverage their partnerships to advance the development of its product portfolio. Through its dedicated efforts, Poxel SA strives to improve the lives of individuals affected by metabolic disorders.
Poxel SA is primarily active in the pharmaceutical industry.
The main competitors of Poxel SA in the market include pharmaceutical companies such as Novo Nordisk, Sanofi, and Eli Lilly.
Poxel SA is a pharmaceutical company specializing in the development of innovative treatments for metabolic diseases. Founded in 2009, the company is headquartered in Lyon, France. Poxel focuses on developing drugs that address unmet medical needs in areas such as type 2 diabetes and non-alcoholic steatohepatitis (NASH). The company's research and development efforts are supported by a robust pipeline and collaborations with renowned academic institutions and strategic partners. Poxel's mission is to improve the lives of patients worldwide by providing effective therapeutic solutions. With its commitment to scientific excellence and patient-centric approach, Poxel is at the forefront of advancing treatments for metabolic diseases.
Poxel SA, a renowned French biopharmaceutical company, has accomplished significant milestones in its journey. Notably, Poxel SA successfully completed the Phase 3 trials for its lead product, Imeglimin, a potential groundbreaking treatment for type 2 diabetes. Additionally, the company received positive feedback from regulatory authorities, advancing its development plans globally. Furthermore, Poxel SA secured strategic partnerships and collaborations with esteemed organizations to enhance its research and development efforts. These achievements demonstrate Poxel SA's dedication to revolutionizing healthcare through innovative therapies.
Poxel SA is primarily present in various countries and regions worldwide. The company has a strong presence in Europe, with a focus on France, Germany, and Italy. Additionally, Poxel SA operates in North America, particularly in the United States. The company also has a presence in Asia, with key markets including Japan and South Korea. With its global outreach, Poxel SA is constantly expanding its geographical footprint to reach more markets and serve a broader customer base.
Poxel SA represents a strong set of values and corporate philosophy. The company is committed to driving innovation and advancing scientific research in the field of metabolic disorders. Poxel SA prioritizes integrity, professionalism, and collaboration, which are embodied in its dedicated team and partnerships. With a focus on patient-centricity, Poxel SA strives to develop effective treatments for serious conditions like type 2 diabetes and non-alcoholic steatohepatitis. By leveraging its expertise and leveraging cutting-edge technologies, Poxel SA aims to make a positive impact on patients' lives worldwide.
9 analysts currently rate the Poxel stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Poxel to generate revenue of 39.27 M EUR and earnings per share of -1.82 EUR.
The Poxel share (POXEL.PA) is listed on 6 stock exchanges, including: London (0RA2.L), Frankfurt (7PO.F), München (7PO.MU), Paris (POXEL.PA).
Poxel SA is a French biopharmaceutical company focused on developing and marketing groundbreaking therapeutics for the treatment of metabolic diseases. The company collaborates closely with prominent academic institutions and research facilities worldwide to develop innovative solutions aimed at improving patients' quality of life. The company offers a wide range of products, including Imeglimin, a novel molecule that improves mitochondrial function and increases insulin sensitivity in the body. Imeglimin aims to treat type 2 diabetes and other metabolic diseases by directly acting on the insulin sensitivity of cells. Another important product of Poxel SA is PXL770, a small molecule that stimulates the AMPK signaling pathway. This improves insulin sensitivity and can help combat obesity and other metabolic diseases. The company has also entered into a collaboration with Roivant Sciences to develop a treatment program for non-alcoholic steatohepatitis (NASH). This involves testing a compound called PXL065, which is intended to act in the liver and could help reduce inflammation and fibrosis. To finance the development and marketing of these products, Poxel SA utilizes a unique business model that is based on collaboration with strategic partners, as well as clinical studies and licenses. The company works closely with leading players in the pharmaceutical industry to develop and market its products. Through licensing agreements and the sale of research and development to partner companies, the company can bring its products to market and simultaneously finance its research and development activities. Furthermore, Poxel SA employs innovative business models to accelerate the development and marketing of its products. The company is heavily involved in the research and development efforts of its partners, utilizing state-of-the-art scientific methods and technologies. The company also collaborates closely with academic institutions and research facilities to develop new therapies and technologies targeting metabolic diseases. Overall, Poxel SA is an innovative company focused on the development and marketing of metabolic therapies. Through collaboration with other pharmaceutical companies and academic institutions, the company is able to bring its products to market, finance its research and development, and improve the quality of life for patients worldwide.
The expected revenue of Poxel is 39.27 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Poxel is -93.51 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Poxel is currently -0.07. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Poxel stock.
The price-to-sales ratio (P/S) of Poxel is currently 0.18. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Poxel stock.
The Eulerpool Quality Score for Poxel is 2/10.
The ISIN of Poxel is FR0012432516. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Poxel is A14M04. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Poxel is POXEL.PA. The ticker symbol is used to trade Poxel shares on the stock exchange.
Poxel stock
Poxel Ticker
Poxel FIGI
All fundamentals and in-depth analysis of Poxel
Our stock analysis for Poxel stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Poxel. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.